SCCM Resource Library-Emerging Cellular Therapies and Associated Toxicity: What's Different From CAR-T Therapy?

Emerging Cellular Therapies and Associated Toxicity: What's Different From CAR-T Therapy?

Video Transcription

Video Summary

Immunotherapy has emerged as a revolutionary treatment for cancer and other diseases. The use of CAR-T cells, natural killer (NK) cells, T-cell receptor therapy, and tumor-infiltrating lymphocytes (TILs) are some of the approaches being explored. CAR-T cells use the patient's own immune cells to fight cancer by manipulating T cells. However, there are limitations and toxicities associated with CAR-T therapy. NK cells have unique killing mechanisms and can be derived from various sources with a better safety profile. TILs involve extracting and expanding tumor tissue, enhancing it with IL-2, and targeting specific antigens. Intensivists play a crucial role in the monitoring and management of immunotherapy-related toxicities in the intensive care unit.

Asset Subtitle

Pharmacology, 2023

Asset Caption

Type: one-hour concurrent | Evolving Landscape in Critical Care Medicine: Cellular Therapy-Related Toxicity (SessionID 1202444)

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Membership Level Professional

Membership Level Select

Tag Toxicology

Year 2023

Keywords

Immunotherapy

CAR-T cells

NK cells

TILs

toxicities

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.